Barclays lowered the firm’s price target on Charles River (CRL) to $160 from $166 and keeps an Equal Weight rating on the shares post the Q4 report. The biggest question facing investors is if we are at the bottom of the cycle and if the market is putting trough valuations on trough earnings, the analyst tells investors in a research note. The firm says the issue is that there is no clear answer, as Charles River’s visibility remains very limited with regards to industry demand.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River Labs: Hold Rating Amid Uncertain FY25 Outlook Due to Biopharma Demand and DSA Challenges
- Charles River Laboratories Faces Uncertainty in Achieving Cost Savings from Restructuring Efforts
- Charles River Laboratories Reports 2024 Earnings and 2025 Outlook
- Charles River Labs: Mixed Signals in Earnings Call
- Hold Rating Maintained for Charles River Labs Amid Positive Q4 Results and Strategic Cost-Cutting Measures